Australia Stock Exchange release from OPTHEA : Opthea data for OPT-302 in patients with PVC as presented
Australia Stock Exchange release from OPTHEA OPT.AX : Opthea data for OPT-302 in patients with PVC as presented
Recent news on Ceryvyn Therapeutics
See all newsBrief: Ceryvyn Therapeutics Posts FY Profit Attributable A$330.4 Million
Brief: Opthea To Recommence Trading On ASX On Or Around June 3, 2026
Brief: Opthea Says Hamish George Assumes Role Of CFO
Brief: Opthea Logs FY Prelim Loss Attributable $162.8 Mln
Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy (updated)